Tags : Imfinzi

AstraZeneca Reports the US FDA Acceptance of sBLA and Granted

Shots: The sBLA is based P-III CASPIAN study assessing Imfinzi + SOC (etoposide with either cisplatin or carboplatin)/ Imfinzi + tremelimumab + CT vs CT as monothx. in patients with previously untreated extensive-stage SCLC in 200+ centers across 23 countries The P-III CASPIAN study demonstrated improvement in OS (13.0 cs 10.3 mos.) with a reduction […]Read More